Market Overview

Wedbush Reiterates Outperform Rating, $4 PT on Novavox on New Avian Influenza Reports

Share:

In a report published Friday, Wedbush analyst Gregory R. Wade reiterated an Outperform rating and $4.00 price target on Novavox (NASDAQ: NVAX).

In the report, Wade noted, “From China, there have been recent reports of a lethal new avian influenza virus (H7N9) that has reportedly killed six people, and seriously sickened several others. The New York Times is also reporting that the CDC is beginning work to generate a strain of virus that may, through egg-based culture methods, generate a vaccine. Recall that NVAX's technology avoids the need to generate a new virus. Rather, it incorporates the genetic material for the corresponding viral antigens into its expression system. This system avoids the risks of egg-based manufacturing, such as expression levels in eggs, as the NVAX manufacturing system robustly generates high volumes of vaccine, and NVAX's techniques can potentially produce new vaccines much more rapidly (in weeks) than egg-based systems that can take about 6 months.”

Novavax closed on Thursday at $2.36.

Latest Ratings for NVAX

DateFirmActionFromTo
Nov 2020HC Wainwright & Co.MaintainsBuy
Aug 2020HC Wainwright & Co.MaintainsBuy
Aug 2020B. Riley FBRMaintainsBuy

View More Analyst Ratings for NVAX
View the Latest Analyst Ratings

 

Related Articles (NVAX)

View Comments and Join the Discussion!

Posted-In: WedbushAnalyst Color Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
IPARDA DavidsonMaintains50.0
ASANPiper SandlerUpgrades33.0
WORKPiper SandlerDowngrades45.0
CRMPiper SandlerMaintains278.0
PRGKeyBancInitiates Coverage On65.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com